Pharmalot By Ed Silverman Pharmalittle: FDA OKs new type of diabetes drug from Lilly; Early-stage biotechs are juicy targets for M&A surge
Color Code By Nicholas St. Fleur A ‘city on fire’: How Miami shaped a disputed diagnosis used to justify deaths in police custody
Biotech By Kate Sheridan When biotech acquisitions spike, early-stage startups are prime targets, analysis shows
Exclusive By Nicholas Florko Senate FDA legislation will include dietary supplement, cosmetic reforms
Pharmalot By Ed Silverman Insulin costs for U.S. patients nearly doubled from 2012 through 2016, but usage was flat
Pharmalot By Ed Silverman Bernie Sanders calls for federal investigation of insulin makers for price collusion
Business By Rebecca Robbins The insulin market is heading for a shakeup. But patients may not benefit
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Some docs say more patients want do-it-yourself EpiPens